Pipeline Tracker
Track competitor pipeline assets across your disease states of interest
NV
Filter by Disease State
Customize Table Columns
Company
Asset
Indication
Phase
MOA
Status
Start Date
Completion Date
Pipeline Assets
Sort by:
| Company | Asset | Indication | Phase | MOA | Status | Start Date | Completion Date | Last Update |
|---|---|---|---|---|---|---|---|---|
| Pfizer | PF-06863135 | Multiple Myeloma | Phase 3 | BCMA-targeted | Active | May 28, 2025 | June 2027 | May 28, 2025 |
| Roche | RG-6234 | Multiple Myeloma | Phase 1 | Novel target | New | May 26, 2025 | December 2026 | May 26, 2025 |
| BMS | BMS-986393 | Multiple Myeloma | Phase 2 | CELMoD | Active | January 15, 2025 | March 2027 | May 20, 2025 |
| BMS | BMS-986165 | Psoriasis (Adolescent) | Regulatory | TYK2 inhibitor | Submitted | September 10, 2024 | July 2025 | May 24, 2025 |
| Eli Lilly | LY-3471851 | Psoriasis | Phase 2 | IL-23 inhibitor | Active | March 5, 2025 | April 2027 | May 15, 2025 |
| AstraZeneca | AZD-1402 | Severe Asthma | Phase 3 | IL-13 inhibitor | Active | January 15, 2024 | December 2025 | May 27, 2025 |
| GSK | GSK-3511294 | Severe Asthma | Phase 2 | IL-5 inhibitor | Active | February 20, 2025 | March 2027 | May 10, 2025 |
| Pfizer | PF-07104091 | Breast Cancer (HR+/HER2-) | Phase 2 | CDK inhibitor | Active | April 5, 2025 | May 2027 | May 5, 2025 |
| AstraZeneca | AZD-5991 | Breast Cancer (TNBC) | Phase 1/2 | MCL1 inhibitor | Active | March 15, 2025 | June 2027 | May 1, 2025 |
Showing 1 to 8 of 24 results
© 2025 CI Agent. All rights reserved.